1. Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients.
- Author
-
Campregher PV, Hamerschlak N, Colturato VA, Mauad MA, de Souza MP, Bouzas LF, Tavares Rde C, Barros JC, Chiattone R, Paz A, Silla L, Vigorito AC, Miranda E, Funke VA, and Flowers ME
- Subjects
- Adolescent, Adult, Aged, Allografts, Child, Child, Preschool, Disease-Free Survival, Female, Follow-Up Studies, Graft vs Host Disease etiology, Humans, Infant, Male, Middle Aged, Retrospective Studies, Survival Rate, Bone Marrow Transplantation, Graft vs Host Disease mortality, Hematologic Neoplasms mortality, Hematologic Neoplasms therapy, Peripheral Blood Stem Cell Transplantation, Tissue Donors
- Abstract
Objectives: The objective of this study was to compare the major transplant outcomes between patients receiving hematopoietic stem cell transplantation (HSCT) from bone marrow (BM) or peripheral blood stem cells (PBSC)., Methods: All consecutive HSCT patients using BM or PBSC from an HLA-matched related donors for haematological malignancies after high intensity conditioning at seven Brazilian transplant centres between January 2008 and December 2009 were retrospectively evaluated., Results: In the study period, 334 patients were treated in the centres and included in the evaluation. The cumulative incidence of grades II-IV and III-IV acute graft-versus-host disease (GVHD) at one year was 36.7% and 9.7% for BM recipients and 34.4% and 15.1% for PBSC recipients, respectively (not statistically different). The cumulative incidence of chronic GVHD at three years was 53.7% and 79.8% (HR 1.93; 95% CI 1.38-2.69, P < 0.001) for BM and PBSC, respectively. Median overall survival was 2.85 and 2.39 years for BM and PBSC recipients, respectively (HR 1.19; 95% CI, 0.84-1.68, P = 0.34)., Conclusions: Our results confirm previous findings of increased chronic GVHD incidence in patients receiving PBSC when compared to patients receiving BM as the graft source in HSCT. Acute GVHD incidence, progression-free survival and overall survival were not different between the groups., (© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF